Search Protocols under revision. Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Lymphoblastic LeukaemiaAcute Myeloid LeukemiaChronic Myeloid LeukemiaStem Cell Transplantation, AllogeneicSubgroupalso in pregnancyBCR-ABL negativeT315I mutationICD10C91.0-C92.0-C92.1-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-MeSHHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaTransplantation ConditioningSequencePACE / OPTIC: PONA45, CML (PID950) -|- PONA15, CML (PID3173)ChemotherapyChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibChemo-substanceAsciminibBosutinibDasatinibImatinibInterferon alpha-2a pegylatedNilotinibPonatinibRopeginterferon alfa-2bRuxolitinibNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneEtoposide phosphateFluconazoleFosaprepitantGranisetronUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneEtoposide phosphateFluconazoleFosaprepitantGranisetronUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneEtoposide phosphateFluconazoleFosaprepitantGranisetronUrsodeoxycholic acidValaciclovirSupportive substanceBalanced Crystalloid SolutionCiprofloxacinCotrimoxazoleDexamethasoneEtoposide phosphateFluconazoleFosaprepitantGranisetronUrsodeoxycholic acidValaciclovirNo. Substances210Protocol classificationTherapy classificationalternativecurrent standardIntensityKonditionierung, myeloablativ (MAC)Standard doseTherapy indicationFirst lineSecond lineseveral possibleThird line Therapy phaseallogene StammzelltransplantationTherapy intentioncurativedisease controlRisksAlopeciaAnemia Hb below 8g/dlArthalgiaBleedingCardiotoxicityDiarrheaEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHeart FailureHemorrhageHyperglycemiaHypertensionHypophosphatemiaIncrease AminotransferasesIncrease in lipaseInfectionsLymphopeniaMyalgiasNeutropeniaPainPleural EffusionPneumoniaPruritusPyrexiaQTc Time ExtensionRashThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorBlume KGBurchert ACortes JCortes JEDao KTHochhaus AKantarjian JLipton JO´Brien SPreudhomme CRéa DSaglio GDiseaseAML/ALL/CML, allogene StammzelltransplantationAtypische chronische myeloische Leukämie, BCR-ABL-negativChronische myeloische Leukämie, chronische Phase, Erstlinie, ECOG 0-2Chronische myeloische Leukämie, Ph+/BCR-ABL+, ErstlinieChronische myeloische Leukämie, Ph/BCR-ABL+, IFN-naivChronische myeloische Leukämie, T315I Mutation, nach mind. 1 TKIchronisch myeloische Leukämie, Ph+/BCR-ABL+, Drittlinie und höherCML in stabiler Remission, mind. 3 TKI-Therapie, CML oder Ph+/BCR+ ALL, resistent auf Dasatinib oder Nilotinib, ECOG 0-2Neudiagnostizierte, chronische myeloische Leukämie, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile Granulozyten, ECOG 0-2neudiagnostizierte, Ph+/BCR-ABL+, chronisch myeloische Leukämie, ECOG 0-1Ph+/BCR-ABL+ chronische myeloische Leukämie, chronische Phase < 15% Blasten, < 20% basophile GranulozytenOriginCity of Hope National Medical Center, California, USADepartment of Leukemia, MD Anderson Cancer Center Houston, TX; OPTIC trialDepartment of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, PACE trialDMU Hématologie, Hôpital Saint-Louis, Paris, France, ASCEMBL trialGeorgia Cancer Center at Augusta University, Augusta, USAGerman CML-Study Group, ENDURE/CML-IX trialKnight Cancer Institute, Oregon Health and Science University, Portland, USALaboratoire d’Hématologie, Centre Hospitalier Universitaire, Lille, SPIRIT trialPrincess Margaret Cancer Centre University of TorontoThe University of Texas MD Anderson Cancer Center, Houston, TX, BELA trialUniversity of Newcastle, Newcastle, United Kingdom, IRIS InvestigatorsUniversity of Texas M.D. Anderson Cancer Center, Houston, DASISION trialUniversity of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy, ENESTnd InvestigatorsUniversitätsklinikum Jena, Jena, Germany, ASC4FIRST trialProtokolle in Überarbeitung 14 protocols foundAsciminib 200, Chronic Myeloid Leukemia (PID2826 V1.0)Asciminib 40, Chronic Myeloid Leukemia (PID2144 V1.0)Asciminib 80, Chronic Myeloid Leukemia (PID2941 V1.0)Bosutinib 500, Chronic Myeloid Leukemia (PID946 V1.1)Dasatinib 100, Chronic Myeloid Leukemia (PID940 V1.0)Etoposidphosphat 60 / TBI 13,2, allogene Stammzelltransplantation, MAC (PID3221 V1.0)Imatinib 400 / peginterferon alpha-2a 90, Chronic Myeloid Leukemia (PID952 V1.2)Imatinib 400, Chronic Myeloid Leukemia (PID934 V1.1)Nilotinib 300, Chronic Myeloid Leukemia (PID938 V1.2)Peginterferon alpha-2a 450, Chronic Myeloid Leukemia (PID951 V2.0)Ponatinib 15, Chronic Myeloid Leukemia (PID3173 V1.0)Ponatinib 45, Chronic Myeloid Leukemia (PID950 V1.0)Ropeginterferon Alfa-2b 100, Chronic Myeloid Leukemia (PID3072 V1.0)Ruxolitinib 15, Chronic Myeloid Leukemia, atypical (PID1649 V1.0)
